
CAS 1036959-27-9
:Formel:C17H25N3O2
InChl:InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m1/s1
InChI Key:SYOKIDBDQMKNDQ-JULPFRMLSA-N
SMILES:C1C[C@@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
Filtern nach
Reinheitsanteil
0
100
|
0
|
50
|
90
|
95
|
100
8 Produkte gefunden.
- Niedrigster Preis
- Höchster Preis
- Niedrigste Reinheit
- Höchste Reinheit
- Schnellste Lieferung
(2R)-Vildagliptin ((R)-1-[N-(3-Hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile)
CAS:Heterocyclic compounds with nitrogen hetero-atom(s) only, excluding aromatic or modified aromaticFormel:C17H25N3O2Farbe und Form:Off-White PowderMolekulargewicht:303.19468(2R)-1-(2-((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
CAS:(2R)-1-(2-((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrileFormel:C17H25N3O2Reinheit:99%Molekulargewicht:303.41(2R)-Vildagliptin
CAS:Applications (2R)-Vildagliptin is an oral anti-hyperglycemic agent that inhibit dipeptidyl peptidase 4 (DPP-4) which can act as a serine exopeptidase. Aside from there use in type 2 diabetes, gliptins have positive cardiovascular and anti-inflammtatory effects. Antidiabetic.
References Ahren, B., et al.: J. Clin. Endocrinol. Metab., 89, 2078 (2004), Ahren, B., et al.: Diabetes Care, 27, 2874 (2004), Barlocco, D., et al.: Curr. Opin. Invest. Drugs, 5, 1094 (2004),Formel:C17H25N3O2Farbe und Form:NeatMolekulargewicht:303.4(2R)-Vildagliptin
CAS:(2R)-1-(2-((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrileFormel:C17H25N3O2Reinheit:99%Molekulargewicht:303.4(2R)-1-[2-[(3-Hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile
CAS:(2R)-1-[2-[(3-Hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile is a drug that belongs to the class of DPP-IV inhibitors and is used for the treatment of type 2 diabetes mellitus. It has been shown to be effective in reducing postprandial blood glucose levels in patients with type 2 diabetes mellitus. The mechanism of action of this drug is not fully understood, but it may have an effect on insulin release from pancreatic beta cells and/or inhibition of gastric emptying or intestinal absorption of glucose. This drug has been shown to reduce tubulointerstitial injury in diabetic rats and can be used as a combination therapy for type 2 diabetes mellitus. There are no known clinically relevant interactions between (2R)-1-[2-[(3-HydroxytricycloFormel:C17H25N3O2Reinheit:Min. 95%Molekulargewicht:303.4 g/mol







